Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Shreelekha Deshpande

Internal Medicine Terre Haute, IN Medical Doctor

NPI 1740260710 CMS profile 1124620

4320 S 7Th St, Terre Haute, IN 47802

Open in the dashboard

General payments

$12,740

653 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shreelekha Deshpande of Terre Haute, IN is reported in the CMS Open Payments database as having received $12,740 across 653 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,945 90
2024 General $2,352 126
2023 General $2,318 123
2022 General $2,332 123
2021 General $2,515 122
2020 General $1,279 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shreelekha Deshpande
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Shreelekha Deshpande were reported at $1,945. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Shreelekha Deshpande Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $1,279 $119 $33–$402 $114
2021 $2,515 $135 $37–$521 $132
2022 $2,332 $141 $42–$496 $149
2023 $2,318 $149 $45–$519 $160
2024 $2,352 $154 $47–$537 $164
2025 $1,945 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $2,736 84 payments
  2. GlaxoSmithKline, LLC. $2,004 156 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,301 53 payments
  4. Grifols USA, LLC $654 42 payments
  5. Genzyme Corporation $623 22 payments
  6. Novo Nordisk Inc $612 40 payments
  7. Amgen Inc. $588 38 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $424 22 payments
  9. Regeneron Healthcare Solutions, Inc. $416 16 payments
  10. Idorsia Pharmaceuticals US Inc $278 4 payments
  11. Other $3,104 176 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $12,679 650 payments
  2. Education $61 3 payments
Products named General payments · program years 2020–2025
  1. TRELEGY ELLIPTA $1,270 98 payments
  2. FASENRA $825 10 payments
  3. DUPIXENT $782 24 payments
  4. TEZSPIRE $715 18 payments
  5. BREZTRI $686 17 payments
  6. Prolastin-C Liquid $609 39 payments
  7. OFEV Respiratory $507 21 payments
  8. FARXIGA $438 16 payments
  9. OFEV Respiratory $412 15 payments
  10. Ozempic $402 25 payments
  11. Other $7,703 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

7,519

Median for Internal Medicine: 777

Drug cost

$600,905

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 135 $144,288
Mounjaro Tirzepatide Brand 59 $63,652
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 56 $49,592
Eliquis Apixaban Brand 59 $44,396
Linzess Linaclotide Brand 34 $32,185
Farxiga Dapagliflozin Propanediol Brand 27 $27,893
Xarelto Rivaroxaban Brand 33 $27,720
Januvia Sitagliptin Phosphate Brand 22 $21,553
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 22 $21,487
Trulicity Dulaglutide Brand 13 $18,894

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$83,535

Of which drugs: $2,265

Medicare patients

186

Average age 70

Services billed

3,038

124 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 50%
COPD 47%
Ischemic heart disease 39%
Depression 34%
Heart failure 33%
Osteoporosis 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 22 22 $1,800
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 32 1,200 $251
Injection, ketorolac tromethamine, per 15 mg J1885 Office 16 141 $72
Injection, methylprednisolone sodium succinate, up to 125 mg J2930 Office 13 15 $55
Injection, ceftriaxone sodium, per 250 mg J0696 Office 36 47 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $282
$282 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $205
$205 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $138
  • Amgen Inc. $66
$204 — —
DUPIXENT
  • GENZYME CORPORATION $115
  • Regeneron Healthcare Solutions, Inc. $85
$200 — —
Prolastin-C Liquid
  • Grifols USA, LLC $144
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

653 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record